Suppr超能文献

结直肠癌肺转移患者的外科治疗:现状与结果。

Surgical treatment of pulmonary metastasis in colorectal cancer patients: Current practice and results.

机构信息

Division of Thoracic Surgery, Centre Hospitalier Vaudois (CHUV), Lausanne, Switzerland.

出版信息

Crit Rev Oncol Hematol. 2018 Jul;127:105-116. doi: 10.1016/j.critrevonc.2018.05.001. Epub 2018 Jun 4.

Abstract

Colorectal cancer (CRC) is a frequently occurring disease, yet diagnosed at a local stage in only 40% of cases. Lung metastases (LM) appear in 5-15% of patients and, left untreated, carry a very poor prognosis. Some CRC patients may benefit from a potentially curative LM resection, but success and benefit are difficult to predict. We discuss prognostic factors of survival after lung metastasectomy in CRC patients under several scenarios (with/ without prior liver metastases; repetitive pulmonary resections). We reviewed all studies (2005-2015) about pulmonary metastases surgical management with curative intent in CRC patients, with a minimum threshold on the number of patients reported (without prior liver metastases: n ≥ 100; with prior resection of liver metastases: n ≥ 50; repetitive thoracic surgery: n ≥ 30). The picture of the prognostic factors of survival is nuanced: surgical management demonstrates clear successes and steady progress, yet there is no single success criterion; stratification of patients and selection bias impact the conclusions. Surgical management of liver and lung metastases may prolong life or cure CRC patients, provided the lesions are fully resected and patients carefully selected. Repeat lung metastasectomy is a safe approach to treat patients in selected cases. In conclusion, there is no standard for surgical management in CRC patients with pulmonary metastases. Patients with isolated unilateral lung metastasis with normal CEA level and no lymph node involvement benefit the most from surgery. Most series report good results in highly selected patients, but instances of long-term disease-free survival remain exceptional.

摘要

结直肠癌(CRC)是一种常见疾病,但只有 40%的病例在局部阶段被诊断出来。肺转移(LM)出现在 5-15%的患者中,如果不治疗,预后非常差。一些 CRC 患者可能受益于潜在的可治愈的 LM 切除术,但成功和获益很难预测。我们在几种情况下(有无肝转移史;重复肺切除术)讨论了 CRC 患者肺转移切除术的生存预后因素。我们回顾了 2005 年至 2015 年期间所有关于 CRC 患者有治愈意向的肺转移手术治疗的研究,报告的患者人数最少(无肝转移史:n≥100;肝转移切除术史:n≥50;重复胸部手术:n≥30)。生存预后因素的情况很复杂:手术管理显示出明显的成功和稳定的进展,但没有单一的成功标准;患者分层和选择偏倚影响结论。只要完全切除病变并仔细选择患者,肝脏和肺部转移的手术治疗可能会延长 CRC 患者的生命或治愈他们。重复肺转移切除术是治疗选定病例患者的安全方法。总之,CRC 肺转移患者的手术管理没有标准。单侧孤立性肺转移、CEA 水平正常且无淋巴结受累的患者最受益于手术。大多数系列报告了高度选择患者的良好结果,但长期无病生存的情况仍然例外。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验